Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of EG-COVII in Healthy Adults
NCT06099613Phase 2Completed
- Sponsor
- EyeGene, Inc.
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EG-COVID in coronavirus disease 2019 (COVID-19), sponsored by EyeGene, Inc. Primary endpoint: Safety and tolerability of EG-COVII at 7 weeks. Started Nov 2023; status: completed.
02
Drugs
EG-COVID
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06099613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099613.